People · Operator
Named in public records as an officer, director or promoter · active 2021–2024 · Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Century Therapeutics, Inc. | — | Pharma | Series D+ | $160.0M | $4.7B | 2021 |
| Tempero Bio, Inc. | — | Biotechnology | Series C | $77.0M | $604.5M | 2024 |
| Via Nova Therapeutics, Inc. | — | Biotechnology | Series A | $5.0M | $102.9M | 2021 |
Joseph Jimenez at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Joseph Jimenez on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Johnson | 1 | 10 |
| Carlo Rizzuto | 1 | 7 |
| Francisco Gimenez | 1 | 7 |
| Ilan Zipkin | 1 | 6 |
| Eli Casdin | 1 | 6 |
| Cynthia Butitta | 1 | 3 |
| Juergen Eckhardt | 1 | 3 |
| Douglas Carr | 1 | 2 |
| Benjamine Liu | 1 | 2 |
| Christian Klee | 1 | 1 |
| Donald Ganem | 1 | 1 |
| Toshikazu Ban | 1 | 1 |
| Osvaldo Flores, Ph.D. | 1 | 1 |
| Julie Shah | 1 | 1 |
| Ricardo Dolmetsch | 1 | 1 |
| Joshua Gertsman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.